Loading
A phase 1/2 trial of AZD4360 in pancreatic ductal adenocarcinoma, run by AstraZeneca, active and no longer recruiting.
Study for AZD4360 in Participants With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06921928 by AstraZeneca, with 31 participants enrolled, started 2025-04-29 and due to reach its primary completion in 2027-03-31. Interventions recorded: AZD4360. Conditions listed: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.